SCHEMBL890634

SCHEMBL890634

O=Cc1nc2ccccn2c(=O)c1Br

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
KDM4E B2RXH2 4/20 0.55
NPSR1 Q6W5P4 2/20 0.55
ALDH1A1 P00352 7/20 0.49
HTT P42858 1/20 0.49
GAA P10253 5/20 0.49
GLA P06280 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 3/20 0.46
GFER P55789 1/20 0.46
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
NPC1 O15118 3/20 0.43
HPGD P15428 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9925517 0.81 KDM4E (0.47) MAPTKDM4ENPSR1ALDH1A1HTT
SCHEMBL2820677 0.81 ALDH1A1 (0.40) MAPTKDM4ENPSR1ALDH1A1HTT
SCHEMBL2820680 0.81 ALDH1A1 (0.40) MAPTKDM4ENPSR1ALDH1A1HTT
SCHEMBL2825619 0.78 KDM4E (0.46) MAPTKDM4ENPSR1ALDH1A1HTT
SCHEMBL2825622 0.78 KDM4E (0.46) MAPTKDM4ENPSR1ALDH1A1HTT
SCHEMBL2821737 0.77 MAPT (0.38) MAPTKDM4ENPSR1ALDH1A1HTT
SCHEMBL2821732 0.77 MAPT (0.38) MAPTKDM4ENPSR1ALDH1A1HTT
SCHEMBL5131549 0.77 KDM4E (0.62) MAPTKDM4ENPSR1ALDH1A1GAA
SCHEMBL2820859 0.77 KMT2A (0.53) MAPTKDM4ENPSR1ALDH1A1GAA
SCHEMBL3235534 0.76 ENPP2 (0.55) MAPTKDM4ENPSR1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
EP-2445898-A2 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES AS PI3K INHIBITORS Amgen, Inc (US) 2012-05-02 EP disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
WO-2010151735-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed
WO-2010151735-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 MAPT 3420/4885KDM4E 1436/4885NPSR1 2664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.